Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

New England Journal of Medicine

Volumn 330, Issue 14, 1994, Pages 956-961

 

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; HEPARIN; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY C7E3 FAB; THROMBOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ATHERECTOMY; BLEEDING; BOLUS INJECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DILATATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; FEMALE; HEART MUSCLE ISCHEMIA; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION; TREATMENT PLANNING;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; ATHERECTOMY, CORONARY; CORONARY DISEASE; CORONARY THROMBOSIS; DOUBLE-BLIND METHOD; FEMALE; HEMORRHAGE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET MEMBRANE GLYCOPROTEINS; PROSPECTIVE STUDIES; RECURRENCE; RISK FACTORS; TREATMENT OUTCOME;

EID: 2242477091     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199404073301402     Document Type: Article

References (37)

1. Gruentzig AR, King SB III, Schlumpf M, Siegenthaler W Long-term follow-up after percutaneous transluminal coronary angioplasty: the early Zurich experience. N Engl J Med 1987; 316: 1127-1132
2. Parisi AF, Folland ED, Hartigan P A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. N Engl J Med 1992; 326: 10-16
3. Lincoff AM, Popma JJ, Ellis SG, Hacker JA, Topol EJ Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile. J Am Coll Cardiol 1992; 19: 926-935
4. Tenaglia AN, Fortin DF, Frid DJ, Long-term outcome following successful reopening of abrupt closure after coronary angioplasty. Am J Cardiol 1993; 72: 21-25
5. Detre KM, Holmes DR Jr, Holubkov R, Incidence and consequences of periprocedural occlusion: the 1985-1986 National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 1990; 82: 739-750
6. Ellis SG, Roubin GS, King SB III, Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty. Circulation 1988; 77: 372-379
7. Ellis SG, Bates ER, Schaible T, Weisman HF, Pitt B, Topol EJ Prospects for the use of antagonists to the platelet glycoprotein IIb/IIIa receptor to prevent post-angioplasty restenosis and thrombosis. J Am Coll Cardiol 1991; 17: Suppl B: 89B-95B
8. Tenaglia AM, Fortin DF, Frid DJ, et al. Individualizing the risk of angioplasty abrupt vessel closure. J Am Coll Cardiol (in press).
9. Moushmoush B, Kramer B, Hsieh AM, Klein LW Does the AHA/ACC task force grading system predict outcome in multivessel coronary angioplasty? Cathet Cardiovasc Diagn 1992; 27: 97-105
10. Myler RK, Shaw RE, Stertzer SH, Unstable angina and coronary angioplasty. Circulation 1990; 82: Suppl II: II-88
11. Schwartz L, Bourassa MG, Lesperance J, Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988; 318: 1714-1719
12. Barnathan ES, Schwartz JS, Taylor L, Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty. Circulation 1987; 76: 125-134
13. Harker LA Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty. Am J Cardiol 1987; 60: Suppl: 20B-28B
14. Coller BS A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest 1985; 76: 101-108
15. Coller BS, Scudder LR Inhibition of dog platelet function by in vivo infusion of F(ab')2 fragments of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor. Blood 1985; 66: 1456-1459
16. Ellis SG, Navetta FI, Tcheng JT, Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty: an initial experience. Coron Artery Dis 1993; 4: 167-175
17. Ryan TJ, Faxon DP, Gunnar RM, Guidelines for percutaneous transluminal coronary angioplasty: a report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). Circulation 1988; 78: 486-502
18. Dougherty KG, Marsh KC, Edelman SK, Gaos CM, Ferguson JJ, Leachman DR Relationship between procedural activated clotting time and in-hospital post-PTCA outcome. Circulation 1990; 82: Suppl IV: IV-189
19. Rath B, Bennett DH Monitoring the effect of heparin by measurement of activated clotting time during and after percutaneous transluminal coronary angioplasty. Br Heart J 1990; 63: 18-21
20. Ogilby JD, Kopelman HA, Klein LW, Agarwal JB Adequate heparinization during PTCA: assessment using activated clotting times. Cathet Cardiovasc Diagn 1989; 18: 206-209
21. Sane DC, Califf RM, Topol EJ, Stump DC, Mark DB, Greenberg CS Bleeding during thrombolytic therapy for acute myocardial infarction: mechanisms and management. Ann Intern Med 1989; 111: 1010-1022
22. Rao AK, Pratt C, Berke A, Thrombolysis in Myocardial Infarction (TIMI) Trial — phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988; 11: 1-11
23. Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med 1987; 82: 703-713
24. Kaplan EL, Meier P Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481
25. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley, 1980.
26. Willerson JT, Golino P, Eidt J, Campbell WB, Buja LM Specific platelet mediators and unstable coronary artery lesions: experimental evidence and potential clinical implications. Circulation 1989; 80: 198-205
27. Yusuf S, Wittes J, Probstfield J, Tyroler HA Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA 1991; 266: 93-98
28. Simoons ML, de Boer MJ, van den Brand MJBM, Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation 1994; 89: 596-603
29. Klein LW, Kramer BL, Howard E, Lesch M Incidence and clinical significance of transient creatine kinase elevations and the diagnosis of non-Q wave myocardial infarction associated with coronary angioplasty. J Am Coll Cardiol 1991; 17: 621-626
30. Hunt AC, Chow SL, Shiu MF, Chilton DC, Cummins B, Cummins P Release of creatine kinase-MB and cardiac specific troponin-I following percutaneous transluminal coronary angioplasty. Eur Heart J 1991; 12: 690-693
31. Pauletto P, Piccolo D, Scannapieco G, Changes in myoglobin, creatine kinase and creatine kinase-MB after percutaneous transluminal coronary angioplasty for stable angina pectoris. Am J Cardiol 1987; 59: 999-1000
32. Spadaro JJ, Ludbrook PA, Tiefenbrunn AJ, Kurnik PB, Jaffe AS Paucity of subtle myocardial injury after angioplasty delineated with MB CK. Cathet Cardiovasc Diagn 1986; 12: 230-234
33. Wall TC, Califf RM, Ellis SG, Lack of impact of early catheterization and fibrin specificity on bleeding complications after thrombolytic therapy. J Am Coll Cardiol 1993; 21: 597-603
34. Califf RM, Harrelson-Woodlief L, Topol EJ Left ventricular ejection fraction may not be useful as an end point of thrombolytic therapy comparative trials. Circulation 1990; 82: 1847-1853
35. Donahue JG, Munoz A, Ness PM, The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med 1992; 327: 369-373
36. Dodd RY The risk of transfusion-transmitted infection. N Engl J Med 1992; 327: 419-421
37. Nelson KE, Donahue JG, Munoz A, Transmission of retroviruses from seronegative donors by transfusion during cardiac surgery: a multicenter study of HIV-1 and HTLV-I/II infections. Ann Intern Med 1992; 117: 554-559